Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, announced today that it has been accepted into the Swiss Innovation’s Agency Innosuisse Core Coaching Program, which provides support for startups to create a focused and agile strategy as a way to build and maintain a well-structured organization.
“Our acceptance into Innosuisse Core Coaching is a great opportunity to successfully develop our business approach,” said Ymmunobio CEO Katrin Rupalla, PhD, MBA. “Our goal is to continue growing a sustainable enterprise focused on the development of novel antibodies for the treatment of gastro-intestinal cancers. I’m really looking forward to working with Innosuisse’s coaches.”
The Start-up Coaching program takes place over three years and is aimed at young companies and their founders. It offers three different programs, each focusing on specific development aspects in a way that is tailored to each startup. The company will work with a lead coach and special coaches on such aspects as fundraising, IP, financial planning and legal aspects. Additionally, participants have the opportunity to take part in global trade fairs and will have access to the Milestone Review in order to report and review progress.
Upon completion of the Core Coaching program, Ymmunobio can request the Innosuisse Certificate, which confirms that the startup is ready for sustainable growth.
To learn more about Ymmunobio’s activities and research, visit the website or reach out to [email protected]
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation. Learn more on Ymmunobio’s website and follow on LinkedIn.
Investor Relations: Dr. Katrin Rupalla, [email protected]